570 related articles for article (PubMed ID: 31820537)
21. The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure.
Khandwalla RM; Grant D; Birkeland K; Heywood JT; Fombu E; Owens RL; Steinhubl SR;
Am J Cardiovasc Drugs; 2021 Mar; 21(2):241-254. PubMed ID: 32978755
[TBL] [Abstract][Full Text] [Related]
22. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
Naser N; Kulić M; Jatić Z
Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
[TBL] [Abstract][Full Text] [Related]
23. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
[TBL] [Abstract][Full Text] [Related]
24. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
[TBL] [Abstract][Full Text] [Related]
25. Relation of Household Income to Access and Adherence to Combination Sacubitril/Valsartan in Heart Failure: A Retrospective Analysis of Commercially Insured Patients.
Johnson AE; Swabe GM; Addison D; Essien UR; Breathett K; Brewer LC; Mazimba S; Mohammed SF; Magnani JW
Circ Cardiovasc Qual Outcomes; 2022 Jul; 15(7):e009179. PubMed ID: 35549378
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the population of Polish patients participating in the TRANSITION study with the international population: a post hoc analysis.
Straburzyńska-Migaj E; Dudek M; Kałużna-Oleksy M; Kolasa J; Nessler J; Ptaszyńska-Kopczyńska K; Rostoff P; Lelonek M
Pol Arch Intern Med; 2023 Jun; 133(6):. PubMed ID: 36633194
[TBL] [Abstract][Full Text] [Related]
27. Use of sacubitril/valsartan early after CABG.
Nurzhanova M; Musagaliyeva A; Zhakypova R; Senkibayeva D; Rakisheva A
Open Heart; 2024 Jan; 11(1):. PubMed ID: 38238027
[TBL] [Abstract][Full Text] [Related]
28. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction.
Dereli S; Kılınçel O; Çerik İB; Kaya A
Acta Cardiol; 2020 Dec; 75(8):774-782. PubMed ID: 32186467
[No Abstract] [Full Text] [Related]
29. Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Carnicelli AP; Li Z; Greiner MA; Lippmann SJ; Greene SJ; Mentz RJ; Hardy NC; Blumer V; Shen X; Yancy CW; Peterson PN; Allen LA; Fonarow GC; O'Brien EC
JACC Heart Fail; 2021 Dec; 9(12):876-886. PubMed ID: 34509408
[TBL] [Abstract][Full Text] [Related]
30. Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis.
Acanfora D; Scicchitano P; Acanfora C; Maestri R; Goglia F; Incalzi RA; Bortone AS; Ciccone MM; Uguccioni M; Casucci G
Clin Drug Investig; 2020 May; 40(5):493-501. PubMed ID: 32193801
[TBL] [Abstract][Full Text] [Related]
31. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
[TBL] [Abstract][Full Text] [Related]
32. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Mann DL; Givertz MM; Vader JM; Starling RC; Shah P; McNulty SE; Anstrom KJ; Margulies KB; Kiernan MS; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; DeVore AD; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JAMA Cardiol; 2022 Jan; 7(1):17-25. PubMed ID: 34730769
[TBL] [Abstract][Full Text] [Related]
33. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV
JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447
[TBL] [Abstract][Full Text] [Related]
34. Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose.
Pharithi RB; Ferre-Vallverdu M; Maisel AS; O'Connell E; Walshe M; Sweeney C; Barton J; McDonald K; O'Hare D; Watson C; Gallagher J; Ledwidge M; McDonald K
ESC Heart Fail; 2020 Feb; 7(1):158-166. PubMed ID: 31903729
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
Morrow DA; Velazquez EJ; DeVore AD; Prescott MF; Duffy CI; Gurmu Y; McCague K; Rocha R; Braunwald E
Eur Heart J; 2019 Oct; 40(40):3345-3352. PubMed ID: 31093657
[TBL] [Abstract][Full Text] [Related]
36. Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.
Gilstrap L; Zipkin RJ; Barnes JA; King A; O'Malley AJ; Gaziano TA; Tosteson ANA
Am Heart J; 2022 Aug; 250():23-28. PubMed ID: 35525261
[TBL] [Abstract][Full Text] [Related]
37. Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.
Chatur S; Claggett BL; Vardeny O; Jering K; Desai AS; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
Eur J Heart Fail; 2023 Jan; 25(1):87-94. PubMed ID: 36181769
[TBL] [Abstract][Full Text] [Related]
38. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
Bhatt AS; Vaduganathan M; Claggett BL; Liu J; Packer M; Desai AS; Lefkowitz MP; Rouleau JL; Shi VC; Zile MR; Swedberg K; Vardeny O; McMurray JJV; Solomon SD
Eur J Heart Fail; 2021 Sep; 23(9):1518-1524. PubMed ID: 34101308
[TBL] [Abstract][Full Text] [Related]
39. Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure.
Carnicelli AP; Lippmann SJ; Greene SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Shen X; Yancy CW; Peterson PN; Allen LA; Fonarow GC; O'Brien EC
J Card Fail; 2021 Aug; 27(8):826-836. PubMed ID: 34364659
[TBL] [Abstract][Full Text] [Related]
40. Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry.
Maggioni AP; Clark AL; Barrios V; Damy T; Drozdz J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Zeymer U;
ESC Heart Fail; 2022 Dec; 9(6):4209-4218. PubMed ID: 36106548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
